Kappa opioid receptor antagonists and products and methods related thereto
Edward Roberts, Fallbrook, CA (US); Miguel A. Guerrero, San Diego, CA (US); Mariangela Urbano, Del Mar, CA (US); Hugh Rosen, La Jolla, CA (US); Robert M. Jones, South San Francisco, CA (US); Candace Mae Laxamana, South San Francisco, CA (US); Xianrui Zhao, South San Francisco, CA (US); and Eric Douglas Turtle, Belmont, CA (US)
Assigned to BLACKTHORN THERAPEUTICS, INC., San Francisco, CA (US); and THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US)
Filed by The Scripps Research Institute, La Jolla, CA (US); and BlackThorn Therapeutics, Inc., San Francisco, CA (US)
Filed on Jul. 30, 2021, as Appl. No. 17/390,531.
Application 16/846,136 is a division of application No. 15/924,119, filed on Mar. 16, 2018, granted, now 10,676,469, issued on Jun. 9, 2020.
Application 17/390,531 is a continuation of application No. 16/846,136, filed on Apr. 10, 2020, granted, now 11,124,504.
Claims priority of provisional application 62/609,960, filed on Dec. 22, 2017.
Claims priority of provisional application 62/585,447, filed on Nov. 13, 2017.
Claims priority of provisional application 62/473,209, filed on Mar. 17, 2017.
Prior Publication US 2022/0162202 A1, May 26, 2022
1. A pharmaceutical composition comprising a compound having the following structure, or a pharmaceutically acceptable hydrate, solvate, isotope or salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient:
